These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31465572)

  • 21. Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia: evidence from a systematic review and meta-analysis.
    Li S; Kwong JS; Zeng XT; Ruan XL; Liu TZ; Weng H; Guo Y; Xu C; Yan JZ; Meng XY; Wang XH
    Sci Rep; 2015 Jul; 5():12002. PubMed ID: 26156138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Null genotypes at the GSTM1 and GSTT1 genes and the risk of benign prostatic hyperplasia: a case-control study and a meta-analysis.
    Choubey VK; Sankhwar SN; Tewari R; Sankhwar P; Singh BP; Rajender S
    Prostate; 2013 Jan; 73(2):146-52. PubMed ID: 22692893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: Hellstrom WJG, et al.: Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia (BPH) and BPH treatment. (Urology 2009;74:15-21).
    Schmid HP; Böhlen D
    Urology; 2009 Dec; 74(6):1377; author reply 1377-8. PubMed ID: 19962542
    [No Abstract]   [Full Text] [Related]  

  • 24. Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review, Meta-analysis, and Cost-Consequence Model.
    Treharne C; Crowe L; Booth D; Ihara Z
    Eur Urol Focus; 2018 Mar; 4(2):270-279. PubMed ID: 28753756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial Comment on: Trends and Perioperative Outcomes Across Major Benign Prostatic Hyperplasia Procedures from the ACS-NSQIP 2011-2015 by Anderson et al. (From: Anderson BB, Heiman J, Large T, et al. J Endourol 2019;33:62-68; DOI: 10.1089/end.2018.0266).
    Mehan N; Stroman L; Challacombe B
    J Endourol; 2019 Jan; 33(1):69-70. PubMed ID: 30221540
    [No Abstract]   [Full Text] [Related]  

  • 28. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis.
    Lee SWH; Chan EMC; Lai YK
    Sci Rep; 2017 Aug; 7(1):7984. PubMed ID: 28801563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review.
    Ilic D; Misso M
    Maturitas; 2012 Aug; 72(4):269-76. PubMed ID: 22633187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
    De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
    Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H; Zong H; Cui Y; Li N; Zhang Y
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
    Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
    Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
    Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
    J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: Chen et al.: Preliminary results of prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-w high-intensity laser (Urology 2010;75:658-663).
    Shenoy SP; Marla PK; Tantry TP
    Urology; 2011 Mar; 77(3):765-6. PubMed ID: 21377024
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost Comparison of Benign Prostatic Hyperplasia Treatment Options.
    DeWitt-Foy ME; Gill BC; Ulchaker JC
    Curr Urol Rep; 2019 Jun; 20(8):45. PubMed ID: 31218458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cernilton for benign prostatic hyperplasia.
    Wilt T; Mac Donald R; Ishani A; Rutks I; Stark G
    Cochrane Database Syst Rev; 2000; (2):CD001042. PubMed ID: 10796739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis.
    Ishani A; MacDonald R; Nelson D; Rutks I; Wilt TJ
    Am J Med; 2000 Dec; 109(8):654-64. PubMed ID: 11099686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prostatic urethral lift: A novel minimally invasive treatment for benign prostatic hyperplasia].
    Liang JY; Lu YP
    Zhonghua Nan Ke Xue; 2016 Aug; 22(8):735-740. PubMed ID: 29019232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thulium (Tm:YAG) laser vaporesection of prostate and bipolar transurethral resection of prostate in patients with benign prostate hyperplasia: a systematic review and meta-analysis.
    Lan Y; Wu W; Liu L; Zhou S; Lan C; Ketegwe IR; Zeng G
    Lasers Med Sci; 2018 Sep; 33(7):1411-1421. PubMed ID: 29947009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.